TABLE 2.
Amprenavir pharmacokinetic parametersa
| Treatment | Cmax,ss (μg/ml) | Cmin,ss (μg/ml) | Tmax,ss (h) | AUC0-10 (μg · h/ml) | AUCss (μg · h/ml) | CL/F (liters/h) |
|---|---|---|---|---|---|---|
| All patients (n = 19) | 5.71 (4.57, 7.13) | 1.64 (1.29, 2.09) | 1.00 (0.48-2.03) | 25.25 (20.62, 30.91) | 28.34 (23.13, 34.71) | 21.17 (17.28, 25.94) |
| APV-RTV (n = 10) | 7.12 (5.11, 9.93) | 1.92 (1.32, 2.79) | 0.95 (0.50-2.00) | 32.06 (24.04, 42.76) | 35.74 (26.62, 47.98) | 16.79 (12.51, 22.54) |
| APV-RTV-EFV (n = 7) | 4.13 (3.14, 5.43) | 1.36 (0.95, 1.97) | 1.00 (0.48-2.03) | 18.70 (15.22, 22.98) | 21.31 (17.23, 26.35) | 28.16 (22.78, 34.82) |
a
Abbreviations: APV, amprenavir; RTV, ritonavir; EFV, efavirenz. CI, confidence interval. Summary statistics are given for patients who received amprenavir and ritonavir and for patients who received amprenavir and ritonavir plus efavirenz. Values are geometric means (95% confidence intervals) for all parameters except Tmax,ss, which is given as the median (range).